R Dickson

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. ncbi Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal
    Rumona Dickson
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacoeconomics 29:1051-62. 2011
  2. ncbi Putting evidence into practice
    R Dickson
    International Health Division, Liverpool School of Tropical Medicine, England
    World Health Forum 19:311-4. 1998
  3. ncbi Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials
    R Dickson
    International Health Division, Liverpool School of Tropical Medicine, Liverpool L3 5QA
    BMJ 320:1697-701. 2000
  4. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
  5. ncbi Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-93, iii-iv. 2011
  6. ncbi Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
    A Boland
    Liverpool Reviews and Implementation Group, Sherrington Buildings, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:41-8. 2009
  7. ncbi Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacogenomics J 11:1-14. 2011
  8. ncbi The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
    N Fleeman
    Liverpool Reviews and Implementation Group LRiG, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-102. 2011
  9. ncbi Rituximab for the treatment of rheumatoid arthritis
    A Bagust
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:23-9. 2009
  10. ncbi Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    T Brown
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:71-9. 2010

Collaborators

Detail Information

Publications29

  1. ncbi Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal
    Rumona Dickson
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacoeconomics 29:1051-62. 2011
    ..All values were above NICE's perceived willingness-to-pay threshold. After the second Appraisal Committee meeting, the Committee did not recommend the use of erlotinib in this patient population...
  2. ncbi Putting evidence into practice
    R Dickson
    International Health Division, Liverpool School of Tropical Medicine, England
    World Health Forum 19:311-4. 1998
    ....
  3. ncbi Effects of treatment for intestinal helminth infection on growth and cognitive performance in children: systematic review of randomised trials
    R Dickson
    International Health Division, Liverpool School of Tropical Medicine, Liverpool L3 5QA
    BMJ 320:1697-701. 2000
    ..To summarise the effects of anthelmintic drug treatment on growth and cognitive performance in children...
  4. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
    ....
  5. ncbi Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-93, iii-iv. 2011
    ..Hormone receptor status and human epidermal growth factor 2 (HER2) status are two predictive factors that are taken into consideration when estimating the prognosis of patients with breast cancer...
  6. ncbi Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
    A Boland
    Liverpool Reviews and Implementation Group, Sherrington Buildings, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:41-8. 2009
    ..Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted...
  7. ncbi Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacogenomics J 11:1-14. 2011
    ..Further research is required to improve the evidence base and to generate data on clinical validity and clinical utility...
  8. ncbi The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review
    N Fleeman
    Liverpool Reviews and Implementation Group LRiG, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-102. 2011
    ....
  9. ncbi Rituximab for the treatment of rheumatoid arthritis
    A Bagust
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:23-9. 2009
    ....
  10. ncbi Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    T Brown
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:71-9. 2010
    ....
  11. ncbi Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, The Quadrangle, Brownlow Hill, Liverpool, UK
    Health Technol Assess 14:33-9. 2010
    ....
  12. ncbi Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
    J Greenhalgh
    Liverpool Reviews and Implementation Group LRiG, University of Liverpool, Liverpool, UK
    Health Technol Assess 15:1-178. 2011
    ..The primary objective in the treatment of all patients with a history of occlusive vascular events and peripheral arterial disease is to prevent the occurrence of new occlusive vascular events...
  13. ncbi The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation
    M G Cherry
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 16:1-129. 2012
    ..No reviews have yet assessed the clinical effectiveness and cost effectiveness of primary stroke prevention strategies in children with SCD identified to be at high risk of stroke using TCD ultrasonography...
  14. ncbi Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:31-8. 2010
    ..At the time of writing, the guidance/has not yet been published by NICE...
  15. ncbi Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy
    C Martin Saborido
    Liverpool Reviews and Implementation Group LRiG, Liverpool, UK
    Health Technol Assess 14:iii-iv, 1-75. 2010
    ..9 to 1.1), and reported prevalence rates show wide variations depending on age and country. Conventional treatment strategies for PAF focus on the suppression of paroxysms of AF and return to normal sinus rhythm...
  16. ncbi Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
    T Brown
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 17:1-99. 2013
    ..g. stage IIIA) are different from those with advanced disease, who are suitable for palliative treatment only, and therefore the results should be reported separately...
  17. ncbi A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy
    J Hockenhull
    Liverpool Reviews and Implementation Group, Liverpool, UK
    Health Technol Assess 16:III-IV, 1-110. 2012
    ..Pharmalgen® products (ALK Abelló) have had UK marketing authorisation for VIT (as well as diagnosis) of allergy to bee venom (using Pharmalgen Bee Venom) and wasp venom (using Pharmalgen Wasp Venom) since March 1995...
  18. ncbi The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 14:1-157, iii. 2010
    ....
  19. ncbi Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
    C McLeod
    Liverpool Reviews and Implementation Group, University of Liverpool, UK
    Health Technol Assess 13:iii-iv, ix-xi, 1-121. 2009
    ....
  20. ncbi Best supportive care in lung cancer trials is inadequately described: a systematic review
    B Jack
    Faculty of Health, Edge Hill University, Liverpool, and Marie Curie Palliative Care Institute, Liverpool, UK
    Eur J Cancer Care (Engl) 19:293-301. 2010
    ..Inadequate definitions mean that all direct and indirect comparisons in trials comparing active treatments with best supportive care must be interpreted with caution...
  21. ncbi A systematic review of prevention and intervention strategies for populations at high risk of engaging in violent behaviour: update 2002-8
    J C Hockenhull
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 16:1-152. 2012
    ..This review was designed to examine the effectiveness of these interventions when they are developed in mental health and criminal justice populations...
  22. ncbi The effects of biofeedback for the treatment of essential hypertension: a systematic review
    J Greenhalgh
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:1-104. 2009
    ..To assess the evidence for the long-term effectiveness of biofeedback for the treatment of essential hypertension in adults and to model any clinical benefits...
  23. ncbi Erlotinib for the treatment of relapsed non-small cell lung cancer
    C McLeod
    Liverpool Reviews and Implementation Group LRiG, Room B05, Whelan Building, The Quadrangle, Brownlow Hill, University of Liverpool, Liverpool, UK
    Health Technol Assess 13:41-7. 2009
    ..The guidance issued by NICE in February 2007 as a result of the STA states that erlotinib is not recommended for the treatment of locally advanced or metastatic NSCLC...
  24. ncbi Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review
    Y Dundar
    Department of Pharmacology and Therapeutics, University of Liverpool, UK
    QJM 96:103-13. 2003
    ....
  25. ncbi Superiority and equivalence in thrombolytic drugs: an interpretation
    T Walley
    Department of Pharmacology and Therapeutics, University of Liverpool, UK
    QJM 96:155-60. 2003
  26. ncbi Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation
    A Boland
    Liverpool Reviews and Implementation Group, New Medical School, Liverpool, UK
    Health Technol Assess 7:1-136. 2003
  27. ncbi Coronary artery stents: a rapid systematic review and economic evaluation
    R Hill
    Liverpool Reviews and Implementation Group, Liverpool, UK
    Health Technol Assess 8:iii-iv, 1-242. 2004
    ....
  28. ncbi Molecular cloning and functional characterization of murine sphingosine kinase
    T Kohama
    Department of Biochemistry and Molecular Biology, Georgetown University Medical Center, Washington, DC 20007, USA
    J Biol Chem 273:23722-8. 1998
    ..Our data suggest that sphingosine kinase is a prototypical member of a new class of lipid kinases. Cloning of sphingosine kinase is an important step in corroborating the intracellular role of SPP as a second messenger...
  29. ncbi Cloning, expression, and purification of a functional nonacetylated mammalian mitochondrial chaperonin 10
    R Dickson
    Molecular Biology Division, E I duPont de Nemours and Company, Wilmington, Delaware 19880 0402
    J Biol Chem 269:26858-64. 1994
    ..More important, like the authentic protein purified from mitochondria, the recombinant mitochondrial chaperonin 10, but not groES, is functionally compatible with the heptameric chaperonin 60 of mammalian mitochondria...